Vimarsana
Biggest News Aggregation in the World

Good Publication Practice News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Good Publication Practice. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Good Publication Practice Today - Breaking & Trending Today

Moderna : 2024 ESCMID (mRNA-1010) - MarketScreener - Vimarsana News

Moderna : 2024 ESCMID (mRNA-1010) - MarketScreener

Safety and Immunogenicity of an mRNA-Based Seasonal Influenza Vaccine in Healthy Adults Mieke Soens, Raffael...

RNA Interference With Zilebesiran for Mild to Moderate Hypertension - Vimarsana News

RNA Interference With Zilebesiran for Mild to Moderate Hypertension

This phase 2 randomized trial examines the antihypertensive efficacy and safety of different zilebesiran dosing regimens.

Characterizing Obesity in a Large Health Care Delivery System - Vimarsana News

Characterizing Obesity in a Large Health Care Delivery System

The prevalence of obesity in the Sutter Health system between 2015 and 2020 was 35%. Differences by race/ethnicity, health insurance, smoking status, and comorbidities were examined.

Source: ajmc.com
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial - Vimarsana News

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

Objective To assess the efficacy and safety of pyrotinib (an irreversible pan-HER (human epidermal growth factor receptor) inhibitor), trastuzumab, and docetaxel compared with placebo, trastuzumab, and docetaxel for untreated HER2 positive metastatic breast cancer. Design Randomised, double blind, placebo controlled, multicentre, phase 3 trial. Setting 40 centres in China between 6 May 2019 and 17 January 2022. Participants 590 female patients (median age 52 (interquartile range 46-58) years) with untreated HER2 positive metastatic breast cancer. Interventions Eligible patients were randomised...

Source: bmj.com
Primary Care Transformation: A Team-Based Care Model - Vimarsana News

Primary Care Transformation: A Team-Based Care Model

This article presents a descriptive review of a team-based care transformation model in a large primary care network, including core staffing, process improvement, and extended care teams.

Source: ajmc.com